Benefits of Hepatitis C Viral Eradication: A Real-World Nationwide Cohort Study in Taiwan

Chin Wei Chang; Wei Fan Hsu; Kuo Chih Tseng; Chi Yi Chen; Pin Nan Cheng; Chao Hung Hung; Ching Chu Lo; Ming Jong Bair; Chien Hung Chen; Pei Lun Lee; Chun Yen Lin; Hsing Tao Kuo; Chun Ting Chen; Chi Chieh Yang; Jee Fu Huang; Chi Ming Tai; Jui Ting Hu; Chih Lang Lin; Wei Wen Su; Wei Lun Tsai; Yi Hsiang Huang; Chien Yu Cheng; Chih Lin Lin; Chia Chi Wang; Sheng Shun Yang; Lein Ray Mo; Guei Ying Chen; Chun Chao Chang; Szu Jen Wang; Chia Sheng Huang; Tsai Yuan Hsieh; Chih Wen Lin; Tzong Hsi Lee; Lee Won Chong; Chien Wei Huang; Shiuh Nan Chang; Ming Chang Tsai; Shih Jer Hsu; Jia Horng Kao; Chun Jen Liu; Chen Hua Liu; Han Chieh Lin; Pei Chien Tsai; Ming Lun Yeh; Chung Feng Huang; Chia Yen Dai; Wan Long Chuang; Ming Lung Yu; Cheng Yuan Peng

doi:10.1007/s10620-024-08512-8

Benefits of Hepatitis C Viral Eradication: A Real-World Nationwide Cohort Study in Taiwan

Chin Wei Chang, Wei Fan Hsu, Kuo Chih Tseng, Chi Yi Chen, Pin Nan Cheng, Chao Hung Hung, Ching Chu Lo, Ming Jong Bair, Chien Hung Chen, Pei Lun Lee, Chun Yen Lin, Hsing Tao Kuo, Chun Ting Chen, Chi Chieh Yang, Jee Fu Huang, Chi Ming Tai, Jui Ting Hu, Chih Lang Lin, Wei Wen Su, Wei Lun TsaiYi Hsiang Huang, Chien Yu Cheng, Chih Lin Lin, Chia Chi Wang, Sheng Shun Yang, Lein Ray Mo, Guei Ying Chen, Chun Chao Chang, Szu Jen Wang, Chia Sheng Huang, Tsai Yuan Hsieh, Chih Wen Lin, Tzong Hsi Lee, Lee Won Chong, Chien Wei Huang, Shiuh Nan Chang, Ming Chang Tsai, Shih Jer Hsu, Jia Horng Kao, Chun Jen Liu, Chen Hua Liu, Han Chieh Lin, Pei Chien Tsai, Ming Lun Yeh, Chung Feng Huang, Chia Yen Dai, Wan Long Chuang, Ming Lung Yu^*, Cheng Yuan Peng^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Chronic hepatitis C (CHC) increases the risk of liver cirrhosis (LC) and hepatocellular carcinoma (HCC). This nationwide cohort study assessed the effectiveness of viral eradication of CHC. Methods: The Taiwanese chronic hepatitis C cohort and Taiwan hepatitis C virus (HCV) registry are nationwide HCV registry cohorts incorporating data from 23 and 53 hospitals in Taiwan, respectively. This study included 27,577 individuals from these cohorts that were given a diagnosis of CHC and with data linked to the Taiwan National Health Insurance Research Database. Patients received either pegylated interferon and ribavirin or direct-acting antiviral agent therapy for > 4 weeks for new-onset LC and liver-related events. Results: Among the 27,577 analyzed patients, 25,461 (92.3%) achieved sustained virologic response (SVR). The mean follow-up duration was 51.2 ± 48.4 months, totaling 118,567 person-years. In the multivariable Cox proportional hazard analysis, the hazard ratio (HR) for incident HCC was 1.39 (95% confidence interval [CI]: 1.00–1.95, p = 0.052) among noncirrhotic patients without SVR compared with those with SVR and 1.82 (95% CI 1.34–2.48) among cirrhotic patients without SVR. The HR for liver-related events, including HCC and decompensated LC, was 1.70 (95% CI 1.30–2.24) among cirrhotic patients without SVR. Patients with SVR had a lower 10-year cumulative incidence of new-onset HCC than those without SVR did (21.7 vs. 38.7% in patients with LC, p < 0.001; 6.0 vs. 18.4% in patients without LC, p < 0.001). Conclusion: HCV eradication reduced the incidence of HCC in patients with and without LC and reduced the incidence of liver-related events in patients with LC.

Original language	English
Pages (from-to)	3501-3512
Number of pages	12
Journal	Digestive Diseases and Sciences
Volume	69
Issue number	9
DOIs	https://doi.org/10.1007/s10620-024-08512-8
State	Published - Sep 2024

Keywords

Chronic hepatitis C
Direct-acting antiviral agents
Hepatocellular carcinoma
Liver-related events
Taiwan hepatitis C virus registry

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s10620-024-08512-8

Cite this

Chang, C. W., Hsu, W. F., Tseng, K. C., Chen, C. Y., Cheng, P. N., Hung, C. H., Lo, C. C., Bair, M. J., Chen, C. H., Lee, P. L., Lin, C. Y., Kuo, H. T., Chen, C. T., Yang, C. C., Huang, J. F., Tai, C. M., Hu, J. T., Lin, C. L., Su, W. W., ... Peng, C. Y. (2024). Benefits of Hepatitis C Viral Eradication: A Real-World Nationwide Cohort Study in Taiwan. Digestive Diseases and Sciences, 69(9), 3501-3512. https://doi.org/10.1007/s10620-024-08512-8

@article{7630771900ff4a6ea335ba5ca3129cef,

title = "Benefits of Hepatitis C Viral Eradication: A Real-World Nationwide Cohort Study in Taiwan",

abstract = "Background: Chronic hepatitis C (CHC) increases the risk of liver cirrhosis (LC) and hepatocellular carcinoma (HCC). This nationwide cohort study assessed the effectiveness of viral eradication of CHC. Methods: The Taiwanese chronic hepatitis C cohort and Taiwan hepatitis C virus (HCV) registry are nationwide HCV registry cohorts incorporating data from 23 and 53 hospitals in Taiwan, respectively. This study included 27,577 individuals from these cohorts that were given a diagnosis of CHC and with data linked to the Taiwan National Health Insurance Research Database. Patients received either pegylated interferon and ribavirin or direct-acting antiviral agent therapy for > 4 weeks for new-onset LC and liver-related events. Results: Among the 27,577 analyzed patients, 25,461 (92.3%) achieved sustained virologic response (SVR). The mean follow-up duration was 51.2 ± 48.4 months, totaling 118,567 person-years. In the multivariable Cox proportional hazard analysis, the hazard ratio (HR) for incident HCC was 1.39 (95% confidence interval [CI]: 1.00–1.95, p = 0.052) among noncirrhotic patients without SVR compared with those with SVR and 1.82 (95% CI 1.34–2.48) among cirrhotic patients without SVR. The HR for liver-related events, including HCC and decompensated LC, was 1.70 (95% CI 1.30–2.24) among cirrhotic patients without SVR. Patients with SVR had a lower 10-year cumulative incidence of new-onset HCC than those without SVR did (21.7 vs. 38.7% in patients with LC, p < 0.001; 6.0 vs. 18.4% in patients without LC, p < 0.001). Conclusion: HCV eradication reduced the incidence of HCC in patients with and without LC and reduced the incidence of liver-related events in patients with LC.",

keywords = "Chronic hepatitis C, Direct-acting antiviral agents, Hepatocellular carcinoma, Liver-related events, Taiwan hepatitis C virus registry",

author = "Chang, {Chin Wei} and Hsu, {Wei Fan} and Tseng, {Kuo Chih} and Chen, {Chi Yi} and Cheng, {Pin Nan} and Hung, {Chao Hung} and Lo, {Ching Chu} and Bair, {Ming Jong} and Chen, {Chien Hung} and Lee, {Pei Lun} and Lin, {Chun Yen} and Kuo, {Hsing Tao} and Chen, {Chun Ting} and Yang, {Chi Chieh} and Huang, {Jee Fu} and Tai, {Chi Ming} and Hu, {Jui Ting} and Lin, {Chih Lang} and Su, {Wei Wen} and Tsai, {Wei Lun} and Huang, {Yi Hsiang} and Cheng, {Chien Yu} and Lin, {Chih Lin} and Wang, {Chia Chi} and Yang, {Sheng Shun} and Mo, {Lein Ray} and Chen, {Guei Ying} and Chang, {Chun Chao} and Wang, {Szu Jen} and Huang, {Chia Sheng} and Hsieh, {Tsai Yuan} and Lin, {Chih Wen} and Lee, {Tzong Hsi} and Chong, {Lee Won} and Huang, {Chien Wei} and Chang, {Shiuh Nan} and Tsai, {Ming Chang} and Hsu, {Shih Jer} and Kao, {Jia Horng} and Liu, {Chun Jen} and Liu, {Chen Hua} and Lin, {Han Chieh} and Tsai, {Pei Chien} and Yeh, {Ming Lun} and Huang, {Chung Feng} and Dai, {Chia Yen} and Chuang, {Wan Long} and Yu, {Ming Lung} and Peng, {Cheng Yuan}",

note = "Publisher Copyright: {\textcopyright} The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024.",

year = "2024",

month = sep,

doi = "10.1007/s10620-024-08512-8",

language = "English",

volume = "69",

pages = "3501--3512",

journal = "Digestive Diseases and Sciences",

issn = "0163-2116",

publisher = "Springer",

number = "9",

}

Chang, CW, Hsu, WF, Tseng, KC, Chen, CY, Cheng, PN, Hung, CH, Lo, CC, Bair, MJ, Chen, CH, Lee, PL, Lin, CY, Kuo, HT, Chen, CT, Yang, CC, Huang, JF, Tai, CM, Hu, JT, Lin, CL, Su, WW, Tsai, WL, Huang, YH, Cheng, CY, Lin, CL, Wang, CC, Yang, SS, Mo, LR, Chen, GY, Chang, CC, Wang, SJ, Huang, CS, Hsieh, TY, Lin, CW, Lee, TH, Chong, LW, Huang, CW, Chang, SN, Tsai, MC, Hsu, SJ, Kao, JH, Liu, CJ, Liu, CH, Lin, HC, Tsai, PC, Yeh, ML, Huang, CF, Dai, CY, Chuang, WL, Yu, ML & Peng, CY 2024, 'Benefits of Hepatitis C Viral Eradication: A Real-World Nationwide Cohort Study in Taiwan', Digestive Diseases and Sciences, vol. 69, no. 9, pp. 3501-3512. https://doi.org/10.1007/s10620-024-08512-8

TY - JOUR

T1 - Benefits of Hepatitis C Viral Eradication

T2 - A Real-World Nationwide Cohort Study in Taiwan

AU - Chang, Chin Wei

AU - Hsu, Wei Fan

AU - Tseng, Kuo Chih

AU - Chen, Chi Yi

AU - Cheng, Pin Nan

AU - Hung, Chao Hung

AU - Lo, Ching Chu

AU - Bair, Ming Jong

AU - Chen, Chien Hung

AU - Lee, Pei Lun

AU - Lin, Chun Yen

AU - Kuo, Hsing Tao

AU - Chen, Chun Ting

AU - Yang, Chi Chieh

AU - Huang, Jee Fu

AU - Tai, Chi Ming

AU - Hu, Jui Ting

AU - Lin, Chih Lang

AU - Su, Wei Wen

AU - Tsai, Wei Lun

AU - Huang, Yi Hsiang

AU - Cheng, Chien Yu

AU - Lin, Chih Lin

AU - Wang, Chia Chi

AU - Yang, Sheng Shun

AU - Mo, Lein Ray

AU - Chen, Guei Ying

AU - Chang, Chun Chao

AU - Wang, Szu Jen

AU - Huang, Chia Sheng

AU - Hsieh, Tsai Yuan

AU - Lin, Chih Wen

AU - Lee, Tzong Hsi

AU - Chong, Lee Won

AU - Huang, Chien Wei

AU - Chang, Shiuh Nan

AU - Tsai, Ming Chang

AU - Hsu, Shih Jer

AU - Kao, Jia Horng

AU - Liu, Chun Jen

AU - Liu, Chen Hua

AU - Lin, Han Chieh

AU - Tsai, Pei Chien

AU - Yeh, Ming Lun

AU - Huang, Chung Feng

AU - Dai, Chia Yen

AU - Chuang, Wan Long

AU - Yu, Ming Lung

AU - Peng, Cheng Yuan

N1 - Publisher Copyright: © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024.

PY - 2024/9

Y1 - 2024/9

N2 - Background: Chronic hepatitis C (CHC) increases the risk of liver cirrhosis (LC) and hepatocellular carcinoma (HCC). This nationwide cohort study assessed the effectiveness of viral eradication of CHC. Methods: The Taiwanese chronic hepatitis C cohort and Taiwan hepatitis C virus (HCV) registry are nationwide HCV registry cohorts incorporating data from 23 and 53 hospitals in Taiwan, respectively. This study included 27,577 individuals from these cohorts that were given a diagnosis of CHC and with data linked to the Taiwan National Health Insurance Research Database. Patients received either pegylated interferon and ribavirin or direct-acting antiviral agent therapy for > 4 weeks for new-onset LC and liver-related events. Results: Among the 27,577 analyzed patients, 25,461 (92.3%) achieved sustained virologic response (SVR). The mean follow-up duration was 51.2 ± 48.4 months, totaling 118,567 person-years. In the multivariable Cox proportional hazard analysis, the hazard ratio (HR) for incident HCC was 1.39 (95% confidence interval [CI]: 1.00–1.95, p = 0.052) among noncirrhotic patients without SVR compared with those with SVR and 1.82 (95% CI 1.34–2.48) among cirrhotic patients without SVR. The HR for liver-related events, including HCC and decompensated LC, was 1.70 (95% CI 1.30–2.24) among cirrhotic patients without SVR. Patients with SVR had a lower 10-year cumulative incidence of new-onset HCC than those without SVR did (21.7 vs. 38.7% in patients with LC, p < 0.001; 6.0 vs. 18.4% in patients without LC, p < 0.001). Conclusion: HCV eradication reduced the incidence of HCC in patients with and without LC and reduced the incidence of liver-related events in patients with LC.

AB - Background: Chronic hepatitis C (CHC) increases the risk of liver cirrhosis (LC) and hepatocellular carcinoma (HCC). This nationwide cohort study assessed the effectiveness of viral eradication of CHC. Methods: The Taiwanese chronic hepatitis C cohort and Taiwan hepatitis C virus (HCV) registry are nationwide HCV registry cohorts incorporating data from 23 and 53 hospitals in Taiwan, respectively. This study included 27,577 individuals from these cohorts that were given a diagnosis of CHC and with data linked to the Taiwan National Health Insurance Research Database. Patients received either pegylated interferon and ribavirin or direct-acting antiviral agent therapy for > 4 weeks for new-onset LC and liver-related events. Results: Among the 27,577 analyzed patients, 25,461 (92.3%) achieved sustained virologic response (SVR). The mean follow-up duration was 51.2 ± 48.4 months, totaling 118,567 person-years. In the multivariable Cox proportional hazard analysis, the hazard ratio (HR) for incident HCC was 1.39 (95% confidence interval [CI]: 1.00–1.95, p = 0.052) among noncirrhotic patients without SVR compared with those with SVR and 1.82 (95% CI 1.34–2.48) among cirrhotic patients without SVR. The HR for liver-related events, including HCC and decompensated LC, was 1.70 (95% CI 1.30–2.24) among cirrhotic patients without SVR. Patients with SVR had a lower 10-year cumulative incidence of new-onset HCC than those without SVR did (21.7 vs. 38.7% in patients with LC, p < 0.001; 6.0 vs. 18.4% in patients without LC, p < 0.001). Conclusion: HCV eradication reduced the incidence of HCC in patients with and without LC and reduced the incidence of liver-related events in patients with LC.

KW - Chronic hepatitis C

KW - Direct-acting antiviral agents

KW - Hepatocellular carcinoma

KW - Liver-related events

KW - Taiwan hepatitis C virus registry

UR - http://www.scopus.com/inward/record.url?scp=85197505246&partnerID=8YFLogxK

U2 - 10.1007/s10620-024-08512-8

DO - 10.1007/s10620-024-08512-8

M3 - Article

C2 - 38965159

AN - SCOPUS:85197505246

SN - 0163-2116

VL - 69

SP - 3501

EP - 3512

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

IS - 9

ER -

Benefits of Hepatitis C Viral Eradication: A Real-World Nationwide Cohort Study in Taiwan

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this